What are the mechanisms of action of guideline‑directed medical therapy (GDMT) medications for heart failure?

Mechanisms of Action of GDMT Medications for Heart Failure

Guideline-directed medical therapy for heart failure with reduced ejection fraction consists of four foundational drug classes that target distinct pathophysiologic pathways: renin-angiotensin system inhibitors block neurohormonal activation, beta-blockers reduce sympathetic overdrive and myocardial oxygen demand, mineralocorticoid receptor antagonists prevent aldosterone-mediated fibrosis and remodeling, and SGLT2 inhibitors improve myocardial energetics and reduce sodium retention. 1

Core GDMT Drug Classes and Their Mechanisms

Renin-Angiotensin System (RAS) Inhibitors

ACE Inhibitors, ARBs, and ARNIs (Angiotensin Receptor-Neprilysin Inhibitors):

• ACE inhibitors block the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sympathetic activation while decreasing afterload and preventing maladaptive ventricular remodeling 2

• ARBs directly block angiotensin II type 1 receptors, producing similar hemodynamic and neurohormonal effects as ACE inhibitors 2

• ARNIs (sacubitril/valsartan) combine angiotensin receptor blockade with neprilysin inhibition, which increases natriuretic peptides (BNP, ANP), promoting vasodilation, natriuresis, and inhibition of maladaptive remodeling 3

  • The neprilysin inhibition component enhances endogenous counter-regulatory mechanisms against neurohormonal activation 3
  • ARNIs demonstrate superior left ventricular reverse remodeling compared to ACE inhibitors alone, with significant reductions in LV volumes and increases in ejection fraction 3

Beta-Blockers

• Mechanism: Competitively block beta-adrenergic receptors, reducing excessive sympathetic nervous system activation that characterizes heart failure 2

• Effects: Decrease heart rate, reduce myocardial oxygen consumption, prevent catecholamine-induced myocyte toxicity, and allow time for diastolic filling 2

• Dose-dependent benefits include improvements in LVEF, reduction in HF hospitalizations, and reduction in all-cause mortality 2

Mineralocorticoid Receptor Antagonists (MRAs)

• Mechanism: Block aldosterone receptors in the heart, vasculature, and kidneys, preventing aldosterone-mediated sodium retention, potassium wasting, myocardial fibrosis, and vascular dysfunction 1

• Effects: Reduce ventricular remodeling, decrease arrhythmias, and improve endothelial function beyond simple diuretic effects 1

• Non-steroidal MRAs (finerenone) provide similar benefits with improved selectivity and potentially fewer hyperkalemia concerns 4

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

• Mechanism: Inhibit SGLT2 in the proximal renal tubule, promoting urinary glucose and sodium excretion independent of insulin 1

• Pleiotropic cardiac effects include:

  • Improved myocardial energetics through enhanced ketone body utilization 5
  • Reduced ventricular preload and afterload through osmotic diuresis 5
  • Anti-inflammatory and anti-fibrotic effects 5
  • Improved mitochondrial function and reduced oxidative stress 5

• Universal benefit: SGLT2 inhibitors provide benefit across the entire ejection fraction spectrum (HFrEF, HFmrEF, HFpEF), making them foundational therapy regardless of EF 4, 5

Additional GDMT Medications

Hydralazine-Isosorbide Dinitrate Combination

• Hydralazine: Direct arterial vasodilator that reduces afterload 2

• Isosorbide dinitrate: Venodilator that reduces preload through nitric oxide-mediated mechanisms 2

• Combined effect: Reduces both preload and afterload, decreasing myocardial wall stress and oxygen demand 2

• Specific indication: Particularly effective in African American patients with HFrEF who remain symptomatic despite ACE inhibitor, beta-blocker, and MRA therapy 2

Ivabradine

• Mechanism: Selectively inhibits the If (funny) current in the sinoatrial node, reducing heart rate without negative inotropic effects 2

• Indication: For patients with HFrEF in sinus rhythm with heart rate ≥70 bpm despite maximally tolerated beta-blocker therapy 2

• Benefit: Reduces HF hospitalizations and cardiovascular death by allowing more complete diastolic filling and reducing myocardial oxygen demand 2

Digoxin

• Mechanism: Inhibits sodium-potassium ATPase pump, leading to increased intracellular calcium and modest positive inotropy, plus vagal enhancement that slows AV nodal conduction 2

• Limited role: May reduce HF hospitalizations but shows no mortality benefit and requires caution due to narrow therapeutic window 2

• Reserved for: Patients who remain symptomatic despite optimization of the four foundational GDMT classes 2

Synergistic Effects and Reverse Remodeling

The combination of these medications produces additive and synergistic effects on left ventricular reverse remodeling:

• Simultaneous or rapid sequential initiation of all four foundational GDMT classes (RAS inhibitor/ARNI, beta-blocker, MRA, SGLT2i) produces substantially greater absolute risk reductions than sequential monotherapy 4

• ARNIs demonstrate particularly robust reverse remodeling effects, with reductions in LV end-diastolic volume (-18%), LV end-systolic volume (-31.8%), and increases in LVEF (+42.1%) after one year 3

• Secondary mitral regurgitation improves in parallel with reverse remodeling, as reduced LV volumes decrease mitral annular dilation and papillary muscle displacement 3

Common Pitfalls

Delayed or sequential initiation: Less than one-fifth of eligible patients receive all four foundational GDMT medications, often due to unnecessary sequential titration strategies 4

Telemedicine limitations: Greater telemedicine use is associated with reduced GDMT initiation, particularly for aldosterone antagonists, highlighting the need for proactive medication optimization regardless of visit modality 6

Age-related underutilization: Older adults (≥75 years) derive substantial benefit from GDMT, including ARNIs, with consistent reductions in cardiovascular and HF hospitalizations across all age strata including those ≥90 years 7